



AI

03/17/98
1c447 U.S. PTO

Certificate of Mailing	
Date of Deposit <u>March 17, 1998</u>	Label Number: <u>EH858743882US</u>
<p>I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.</p>	
<p><u>Sandra E. Marxen</u> Printed name of person mailing correspondence</p>	<p> Signature of person mailing correspondence</p>

UTILITY PATENT APPLICATION TRANSMITTAL UNDER 37 CFR §1.53(b)	
Attorney Docket Number	06632/011001
Applicants	COSTAS N. KARATZAS, JEFFREY D. TURNER, AND ANTHOULA LAZARIS-KARATZAS
Title	PRODUCTION OF BIOFILAMENTS IN TRANSGENIC ANIMALS
PRIORITY INFORMATION:	
<p>This application is a [**continuation/divisional/continuation-in-part**] of and claims priority from United States patent application [**SERIAL NUMBER**], filed [**FILING DATE**].</p> <p>This application claims priority from United States provisional patent application [**SERIAL NUMBER**], filed [**FILING DATE**].</p> <p>This application claims priority from prior foreign patent application [**SERIAL NUMBER**], filed [**FILING DATE**], in [**COUNTRY**].</p>	
APPLICATION ELEMENTS:	
Cover sheet	1 page
Specification	<u>29</u> pages
Claims	4 pages
Abstract	1 page
Drawing	2 pages
Combined Declaration and POA, which is: <input checked="" type="checkbox"/> Unsigned; <input type="checkbox"/> Newly signed for this application; <input type="checkbox"/> A copy from prior application [**SERIAL NUMBER**] and the entire disclosure of the prior application is considered as being part of the disclosure of this new application and is hereby incorporated by reference therein.	3 pages
Statement Deleting Inventors	[**] pages
Sequence Statement	[**] pages
Sequence Listing on Paper	[**] pages

09040518 034792

Sequence Listing on Diskette	[**] pages
Small Entity Statement, which is: <input checked="" type="checkbox"/> Unsigned; <input type="checkbox"/> Newly signed for this application; <input type="checkbox"/> A copy from prior application [**SERIAL NUMBER**] and such small entity status is still proper and desired.	1 pages
Preliminary Amendment	[**] pages
IDS	[**] pages
Form PTO 1449	[**] pages
Cited References	[**] pages
Recordation Form Cover Sheet and Assignment	[**] pages
Assignee's Statement	[**] pages
English Translation	[**] pages
Certified Copy of Priority Document	[**] pages
Return Receipt Postcard	1
FILING FEES:	
Basic Filing Fee: \$790/\$395	\$395.00
Excess Claims Fee: 28 - 20 = 8 x \$11	\$88.00
Excess Independent Claims Fee: 3 - 3 = 0 x \$41	\$0.00
Multiple Dependent Claims Fee: \$135	\$135.00
Total Fees:	\$618.00
<input type="checkbox"/> Enclosed is a check for [**AMOUNT**] to cover the total fees. <input type="checkbox"/> Charge [**AMOUNT**] to Deposit Account No. 03-2095 to cover the total fees. <input checked="" type="checkbox"/> The filing fee is not being paid at this time. <input checked="" type="checkbox"/> Please apply any other charges, or any credits, to Deposit Account No. 03-2095.	
CORRESPONDENCE ADDRESS:	
Paul T. Clark, Esq. Reg. No. 30,162 Clark & Elbing LLP 176 Federal Street Boston, MA 02110	
Telephone: 617-428-0200 Facsimile: 617-428-7045	
Signature 	Date 

Certificate of Mailing

Date of Deposit March 17, 1998

Label Number: EH858743882US

I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as **"Express Mail Post Office to Addressee"** with sufficient postage on the date indicated above and is addressed to BOX PATENT APPLICATION, Assistant Commissioner of Patents, Washington, D.C. 20231.

Sandra E. Marxen
Printed name of person mailing correspondence


Signature of person mailing correspondence

APPLICATION
FOR
UNITED STATES LETTERS PATENT

APPLICANTS : COSTAS N. KARATZAS
JEFFREY D. TURNER
ANTHOULA LAZARIS-KARATZAS

TITLE : PRODUCTION OF BIOFILAMENTS IN TRANSGENIC
ANIMALS

5

The utility of spider silk proteins as “super filaments” has led to attempts to produce recombinant spider dragline silks (Prince *et al.*, Biochemistry 34: 10879-10885, 1995; Fahnestock and Irwin, Appl. Microbiol. Biotechnol. 47: 23-32, 1997; Fahnestock and Bedzyk, Appl. Microbiol. Biotechnol. 47: 33-39, 1997). Although successful expression of spider’s silk has been demonstrated in *E. coli*, significant problems remain, such as instability of the sequences used due to recombination and rearrangement in the repetitive areas of the gene, inefficient transcription, translational pausing and premature termination of synthesis resulting in limitations on the length of the silk that can be produced efficiently (less than or equal to 1000 amino acids), low protein yields (4 to 300 mg/liter), and low solubility of the produced fiber.

Production of synthetic spider dragline silk protein in the methylotropic yeast *Pichia Pastoris* was superior to that of *E. coli* in that longer proteins of at least 1600 amino acids in length could be produced efficiently with no observed size heterogeneity due to premature termination of synthesis and stability of the repetitive sequences in the genes being expressed. Yields of protein in the *Pichia* system were 663 mg/liter; however, only 15% of this was in a soluble form in the yeast cell lysate.

25

We have discovered a method for producing biofilaments (*e.g.*, spider silk protein) in transgenic animals. This method greatly facilitates the production of these proteins, which are useful as “super filaments.”

In a first aspect, the invention features a nucleic acid molecule that includes (i) a nucleic acid sequence encoding a biofilament, (ii) a promoter that directs expression of a polypeptide in milk-producing cells or urine-producing cells, where the promoter is operably linked to the nucleic acid sequence, and (iii) a leader sequence that enables secretion of the biofilament by the milk-producing cells or the urine-producing cells, into the milk or urine of a mammal, respectively.

In a second aspect, the invention features a mammalian embryo whose nucleus contains a nucleic acid molecule that includes (i) a nucleic acid sequence encoding a biofilament, (ii) a promoter that directs expression of a polypeptide in milk-producing cells or urine-producing cells, where the promoter is operably linked to the nucleic acid sequence, and (iii) a leader sequence that enables secretion of the biofilament by the milk-producing cells or the urine-producing cells, into, respectively, milk or urine of the mammal that develops from the nucleic acid molecule-containing embryo. Preferably, the nucleic acid molecule is inserted by artifice.

In a third aspect, the invention features a female mammal in which the genome of the mammary tissue of the female mammal contains a nucleic acid molecule that includes (i) a nucleic acid sequence encoding a biofilament, (ii) a promoter that directs expression of a polypeptide in milk-producing cells, where the promoter is operably linked to the nucleic acid sequence, and (iii) a leader sequence that enables secretion of the biofilament by the milk-producing cells, into milk of the female mammal. Preferably, the female mammal is a rodent, a ruminant, or a goat.

In a fourth aspect, the invention features an animal in which the genome of cells that contribute to urine production in the animal contains a nucleic acid molecule that includes (i) a nucleic acid sequence encoding a biofilament, (ii) a promoter that directs expression of a polypeptide urine-producing cells, where the promoter is operably linked

to the nucleic acid sequence, and (iii) a leader sequence that enables secretion of the biofilament by the urine-producing cells, into urine of the animal. Preferably, the animal is a mammal.

In one embodiment of all of the above aspects of the invention, the biofilament is spider silk (*e.g.*, dragline silk). In another embodiment of all of the above aspects, the nucleic acid molecule includes an intron. In a preferred embodiment, when secreted such that the secretion is subjected to shear forces and mechanical extension, the biofilament has a poly-alanine segment that undergoes a helix to a β -sheet transition, where the transition forms a β -crystal that stabilizes the structure of the biofilament.

In another preferred embodiment of all of the above aspects of the invention, the biofilament has an amorphous domain that forms a β -pleated sheet such that inter- β sheet spacings are between 3 angstroms and 8 angstroms in size. In yet another preferred embodiment, the biofilament has a C-terminal amino acid motif containing an amorphous domain and a crystal forming domain, where the motif has a sequence that is at least 50% identical to SEQ ID NO: 2. In yet another preferred embodiment, the biofilament has a consensus sequence that is at least 50% identical to SEQ ID NO: 3. In

In a fifth aspect, the invention features a method for producing a biofilament that includes the steps of: (a) providing an embryonal cell transfected with a biofilament-encoding nucleic acid molecule that expresses and causes secretion of the biofilament from a cell derived from the transfected embryonal cell; (b) growing the embryonal cell to produce an animal containing biofilament expressing and secreting cells; and (c) isolating the biofilament from the biofilament expressing and secreting cells from the animal.

In a sixth aspect, the invention features a method for producing a biofilament that includes the steps of: (a) providing an animal cell transfected with a nucleic acid molecule that contains (i) a nucleic acid sequence encoding a biofilament, (ii) a promoter

that directs expression of a polypeptide in an animal cell, and (iii) a leader sequence that causes secretion of the biofilament by the cell; (b) culturing the transfected cell; and (c) isolating the biofilament from the culture medium of the cultured transfected cell. In other embodiments, the biofilament has a sequence that is 50% identical to SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 20.

In one embodiment of the fifth and sixth aspects of the invention, the biofilament is spider silk (*e.g.*, dragline silk). In another embodiment, the nucleic acid molecule contains an intron. In yet another embodiment, the animal is a mammal. In a preferred embodiment, when secreted such that the secretion is subjected to shear forces and mechanical extension, the biofilament has a poly-alanine segment that undergoes a helix to a β -sheet transition, where the transition forms a β -crystal that stabilizes the structure of the biofilament.

In another preferred embodiment of the fifth and sixth aspects of the invention, the biofilament has an amorphous domain that forms a β -pleated sheet such that inter- β sheet spacings are between 3 angstroms and 8 angstroms in size. In another preferred embodiment, the biofilament has a C-terminal amino acid motif containing an amorphous domain and a crystal forming domain, the motif having a sequence that is at least 50% identical to SEQ ID NO: 2. In yet another preferred embodiment, the biofilament has a consensus sequence that is at least 50% identical to SEQ ID NO: 3. In other embodiments, the biofilament has a sequence that is 50% identical to SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 20.

5 In a preferred embodiment of all of the above aspects of the invention, where the biofilament is dragline silk, preferably the cell (or animal (*e.g.*, a mammal) developed from the cell) produces both of the polypeptides (*e.g.*, ADF-3 and ADF-4) required to produce the dragline silk at a ratio that is at least 40% of the ratio of these polypeptides produced in the natural source (*e.g.*, in the spider).

10 By "biofilament" is meant a fibrous protein that is normally produced and secreted by any one of a variety of insects and arachnids. Biofilaments are composed of alternating crystalline and amorphous regions. Exemplary biofilaments include spider silk, an externally spun fibrous protein secretion found in a variety of arachnids (*e.g.*, *Nephila clavipes*), and fibroin, an externally spun fibrous protein secretion found in a variety of insects (*e.g.*, *Bombyx mori*). Preferable biofilaments, when secreted such that the secretion is subjected to shear forces and mechanical extension, have a poly-alanine segment, forming a crystal-forming domain, that undergoes a helix to β -sheet transition, forming a β -crystal that stabilizes its structure. Preferably, the amorphous domain of a
15 biofilament forms a β -pleated sheet such that inter- β sheet spacings are between 3 angstroms and 8 angstroms in size, preferably, between 3.5 angstroms and 7.5 angstroms in size.

20 Preferably, a biofilament has a C-terminal portion with an amino acid repeat motif which is between 20-40 amino acids in length, more preferably, 34 amino acids in length, and a consensus sequence which is between 35 and 55 amino acids in length, more preferably 47 amino acids in length. Preferably, a biofilament has an amino acid repeat motif (creating both the amorphous domain and the crystal-forming domain) having a sequence that is at least 50% identical to the sequence of SEQ ID NO: 2, more preferably, at least 70% identical, and most preferably, at least 90% identical to SEQ ID NO: 2.

Preferably, a biofilament has a consensus sequence that is at least 50% identical to the sequence of SEQ ID NO: 3, more preferably, at least 70% identical, and most preferably, at least 90% identical to SEQ ID NO: 3.

By a “promoter” is meant a nucleic acid sequence sufficient to direct transcription.

5 Also included in the invention are those promoter elements which are sufficient to render promoter-dependent gene expression controllable for cell type-specific, tissue-specific or inducible by external signals or agents; such elements may be located in the 5' or 3' regions of the native gene. Preferred promoters of the invention direct transcription of a protein in a milk-producing cell; such promoters include, without limitation, promoters
10 from the following genes: whey acidic protein, α S1-casein, α S2-casein, β -casein, κ -casein, β -lactoglobulin, and α -lactalbumin. Other preferred promoters of the invention direct transcription of a protein in a urine-producing cell (*e.g.*, a uroepithelial cell or a kidney cell); such promoters include, without limitation, the promoter from the uroplakin gene. Yet another preferred promoter of the invention directs transcription of a protein in
15 an embryonal cell.

By a “leader sequence” or a “signal sequence” is meant a nucleic acid sequence which, when operably linked to a nucleic acid molecule, allows for the secretion of the product of the nucleic acid molecule. The leader sequence is preferably located 5' to the nucleic acid molecule. Preferably, the leader sequence is obtain from same gene as the
20 promoter that is used to direct the transcription of the nucleic acid molecule, or is obtained from the gene from which the nucleic acid molecule is derived.

By “culture medium” is meant the medium surrounding a cell, and in which the cell has been living. If the cell is secreting a protein (*e.g.*, a biofilament), the culture medium of the cell will contain the protein secreted by that cell.

25 By a “transfected cell” or a “transformed cell” is meant a cell into which (or into

an ancestor of which) has been introduced, by means of recombinant DNA techniques, a nucleic acid molecule encoding a polypeptide of the invention. Preferably, the cell is a eukaryotic cell from a multicellular animal (*e.g.*, a mammal).

By an "embryonal cell" is meant a cell that is capable of being a progenitor to all the somatic and germ-line cells of an organism. Exemplary embryonal cells are embryonic stem cells (ES cells) and fertilized oocytes. Preferably, the embryonal cells of the invention are mammalian embryonal cells.

By "endogenous," as used herein in reference to a gene or a polypeptide, is meant a gene or polypeptide that is normally present in an animal.

By "germ-line cell" is meant a eukaryotic cell, progenitor, or progeny thereof, which is a product of a meiotic cell division.

By "operably linked" is meant that a nucleic acid molecule and one or more regulatory sequences (*e.g.*, a promoter) are connected in such a way as to permit expression and/or secretion of the product (*i.e.*, a polypeptide) of the nucleic acid molecule when the appropriate molecules (*e.g.*, transcriptional activator proteins) are bound to the regulatory sequences.

By "transgene" is meant any piece of nucleic acid that is inserted by artifice into a cell, or an ancestor thereof, and becomes part of the genome of the animal which develops from that cell. Such a transgene may include a gene which is partly or entirely heterologous (*i.e.*, foreign) to the transgenic animal, or may represent a gene homologous to an endogenous gene of the animal.

By "transgenic" is meant any cell which includes a nucleic acid sequence that has been inserted by artifice into a cell, or an ancestor thereof, and becomes part of the genome of the animal which develops from that cell. Preferably, the transgenic animals are transgenic mammals (*e.g.*, rodents or ruminants). Preferably the nucleic acid

(transgene) is inserted by artifice into the nuclear genome.

Brief Description of the Drawing

Fig. 1A is a schematic representation of the goat β -casein/NcDS-1 construct containing the β -casein promoter and signal sequence, the 1.5 kb NcDS-1 cDNA, and the 3' UTR from β -casein.

Fig. 1B is a schematic representation of the Whey Acidic Protein (WAP)/NcDS-1 construct containing the WAP gene promoter, the WAP signal sequence, a 1.5 kb cDNA encoding dragline silk (NcDS-1), and the 3' end of the WAP gene.

Fig. 1C is a schematic representation of the uroplakin II/NcDS-1 construct containing the promoter and signal sequence from the uroplakin II gene, the NcDS-1 cDNA insert, and the 3' UTR region from the mouse protamine-1 (Mp-1) gene.

Detailed Description

Biofilaments, such as spider silk, have a number of high performance mechanical properties that make them comparable to the “super-filaments” Spectra™ (commercially available from AlliedSignal) or Kevlar™ (commercially available from DuPont). Of particular importance is the energy to break a biofilament, which means that biofilaments can absorb energy when stretched, and dissipate that energy as heat when the stress is removed. Furthermore, biofilaments are resistant to digestion by proteolytic enzymes, and are insoluble in dilute acids and bases.

Biofilaments are a natural source of material that is renewable. Transgenic animals expressing biofilaments, such as the animals described herein, may be managed

as normal livestock using available feedstuffs. Thus, the manufacture of this commodity is domestic and renewable. The truly natural source, the spiders themselves, are, unfortunately, too small to produce significant amounts of this material. In addition, since spiders manifest territorial behavior, they cannot be raised in close quarters for mass production.

The weight of the biofilament is important for ballistic protection applications. The demands in modern ballistic protection demand a flexible and light material that retains its unique mechanical properties. Biofilaments are lighter than Kevlar™, and are more flexible than Spectra™.

I. Spider silk-encoding genes

The size of the native dragline silk protein has not been determined conclusively, but has been observed to range from 274 kDa to 750 kDa. The N-terminus amino acid sequence and the 5'-end nucleic acid sequence have not been elucidated. Partial cDNA clones (spidroin 1 and 2) from *Nephilia clavipes* (the golden orb weaver found in Brazil and southern Florida) and from *Araneus diadematus* (Guerette *et al.*, Science 272: 112-115, 1996) have been isolated and found to be part of the 3'-end of their corresponding genes. A summary of the clones isolated from *Araneus*, and the glands from which they are derived, is shown below in Table 1.

Table 1

Araneus diadematus genes (libraries screened using spidroin-1, 2 from *N. clavipes*)

Distribution-Expression of specific silk type (as determined by Northern Blot)

Gene Cloned	major ampullae gland (producing dragline silk)	minor ampullae gland (producing accessory fiber)	flagelliform gland (producing viscid silk)	aggregate gland (producing viscid silk)	cylindrical gland (producing cocoon silk)
ADF-1	-----	major	-----	-----	-----
ADF-2	-----	-----	-----	-----	minor
ADF-3	major	-----	minor	minor	-----
ADF-4	major	-----	-----	-----	-----

The sequence of ADF-1 (*Araneus diadematus* fibroin) is 68% poly(A)₅ (*i.e.*, AAAAA; SEQ ID NO: 9) or (GA)₂₋₇ (SEQ ID NO: 10), and 32% GGYGQGY (SEQ ID NO: 11); ADF-2 is 19% poly(A)₈ (SEQ ID NO: 12) and 81% [GGAGQGGY (SEQ ID NO: 13) and GGQGGQGGYGGLGSQGA (SEQ ID NO: 14)]; ADF-3 is 21% ASAAAAAA (SEQ ID NO: 15) and 79% [(GPGQQ)_n, where n= 1-8 (SEQ ID NO: 16) and GPGGQGPYGPG (SEQ ID NO: 17)]; and ADF-4 is 27% SSAAAAAAA (SEQ ID NO: 18) and 73% [GPGSQGPS (SEQ ID NO: 19) and GPGGY (SEQ ID NO: 20)].

Any of a variety of procedures well known in the art may be utilized to clone additional biofilament-encoding genes using the known nucleic acid sequences from *Nephila* and *Araneus*, and one so skilled will routinely adapt one of these methods in order to obtain the desired gene. The full length clones of *Nephila* and *Araneus* genes may be likewise isolated.

One such method for obtaining a biofilament-encoding gene sequence is to use an oligonucleotide probe generated by the *Nephila clavipes* spidroin 1 gene sequence

(Arcidiacono *et al.*, Appl. Microbiol. Biotechnol. 49: 31-38, 1998) to screen an arachnid or insect cDNA or genomic DNA library for sequences which hybridize to the probe. Hybridization techniques are well known to the skilled artisan, and are described, for example, in Ausubel *et al.*, *supra*, and Sambrook *et al.*, *supra*. cDNA or genomic DNA library preparation is also well known in the art. A large number of prepared nucleic acid libraries from a variety of species are also commercially available. The oligonucleotide probes are readily designed using the sequences described herein and standard techniques. The oligonucleotide probes may be based upon the sequence of either strand of DNA encoding the spidroin 1 gene product. Exemplary oligonucleotide probes are degenerate probes (*i.e.*, a mixture of all possible coding sequences for the *N. clavipes* spidroin 1 protein).

II. Spider silk formation and spinning

Silks or fibroin monomers are produced within specialized glands in the abdomen of the spider and are retained in a lumen at a concentration of 20-30%. This material will polymerize when tension is applied in the presence of drying. As the silk is very thin, the drying process is rapid. Silks are composed of alternating crystalline and amorphous regions. The dominant crystals are β -pleated sheet crystals that are arranged parallel to the long axis of the silk fiber. In *Bombyx mori* (silkworms), the crystal-forming domain is a six peptide (GAGAGS (SEQ ID NO: 1)) domain which alternates with amorphous domains.

The amino acids G, A, and S make up greater than 85% of silkworms' cocoon silk fibroin. Silk's alternating Ala or Ser and Gly residues extend to opposite sides of a given β -sheet so that the Ala side chains extending from one β -sheet efficiently nestle between those of the neighboring sheet, and likewise for the Gly side chains. Gly side chains from

neighboring β -sheets are in contact, as are those of Ala and Ser. The inter-sheet spacings, consequently, have the alternating values 3.5 angstroms and 5.7 angstroms, as determined from X-ray diffraction studies of *Nephila* dragline silk. This spacing is identical to that of synthetic poly-L-alanine peptides in their β -sheet conformation. X-ray diffraction studies of *Araneus diadematus* dragline silk indicates a larger inter-sheet spacing of about 7.5 angstroms (Gosline *et al.*, Biomimetics: Design and Processing of Materials, pp: 237-261, eds. Sarikaya and Aksay, Amer. Inst. of Physics, 1995).

In *Nephila*, the major ampullae gland (MA gland) produces the dragline silk. The C-terminal portion of the *Nephila* MA-gland produced genes cloned so far (spidroin 1 and spidroin 2) have the following sequences: a 34 amino acid long repeat motif (forming both the amorphous domain and crystal-forming domain); and a 47 amino acid long consensus sequence (Xu and Lewis, Proc. Natl. Acad. Sci. U.S.A. 87: 7120-7124, 1990; Beckwitt and Arcidiacono, J. Biol. Chem. 269: 6661-6663, 1994).

The 34 amino acid long repeat motif (forming both the amorphous domain and crystal-forming domain) of *Nephila* spidroin 1 has the following sequence:
AGQ GGY GGL GSQ GAG RGG LGG QGA GAA AAA AAG G (SEQ ID NO: 2).
Note the poly-alanine region (AAAAAAA) at the C-terminal end of SEQ ID NO: 2, as well as numerous glycine blocks forming amorphous domains (two glycine residues separated by 3 amino acids; *e.g.*, GG LGG).

The 47 amino acid long consensus sequence of *Nephila* spidroin 2 has the following sequence:
CPG GYG PGQ QCP GGY GPG QQC PGG YGP GQQ GPS GPG SAA AAA
AAA AA (SEQ ID NO: 3).

The silk is secreted within individual glands; when the secretion is subjected to shear forces and mechanical extension, the poly-alanine (crystal-forming) segments

undergo a helix to β -sheet transition, forming β -crystals that stabilize its structure. The glycine blocks are designated as portions forming the amorphous polypeptide chains interspersed among the crystalline regions.

Biofilaments have evolved in certain insects and arachnids having very specialized anatomical adaptations and gene evolution. In spiders, the silk is produced by a series of abdominal glands. The formation and size of the crystal may depend upon, among other things, the primary amino acid sequence composition. The production and secretion of the major silks occurs in the major ampullae (MA) gland, the flagelliform (FL) gland, and the cylindrical (CY) gland, which produce dragline silk, viscid silk, and cocoon silk, respectively. It will be understood that the transgenic animals described herein, and the constructs used to generate such animals, may produce any of these biofilaments, or any variations thereof, such that a biofilament is produced having inter- β -sheet spacings of between 3.5 to 7.5 angstroms.

A. Dragline Silk.

The MA gland produces two proteins, at a 3:2 ratio, which are rich in glycine, alanine, and proline. These proteins form the dragline silk, which is the lifeline, the scaffolding silk, and the frame for spider webs. Dragline silk is a high stiffness fiber and has properties similar to nylon. Dragline silk contains 20-30% crystal, by volume, and has the following characteristics: stiff (initial Young's modulus is 10 GPa), strong (tensile strength is 1.5 GPa), and tough (energy required to break is 150 MJm⁻³).

B. Viscid Silk

The viscid silk produced by the FL gland forms the sticky spiral of the web. No genes encoding viscid silk have been identified as yet. Viscid silk contains less than 5% crystal by volume, is elastomeric in its native state, and has properties similar to Lycra. It has the following characteristics: mechanically similar to lightly cross-linked rubber (e.g.,

spandex), low stiffness (initial Young's modulus is 3 MPa), and highly extensible.

C. Cocoon Silk

The CY gland produces cocoon silk that is similar to the cocoon silk produced by silkworms (*B. mori*).

5 III. Synthesis of biofilament genes

Because of the difficulties encountered in cloning native silk genes, synthetic genes can be cloned and expressed. The cDNA sequences cloned to date share similarities in overall organization and in regions of sequence conservation. The consensus repeats are rich in glycine and glutamine, with poly (Ala) regions integrated
10 into larger repeating units.

For discussion purposes, the candidate gene will be represented by one of the major dragline genes from *N. clavipes*, spidroin 1 (Arcidiacono *et al.*, Appl. Microbiol. Biotechnol. 49: 31-38, 1998). The highly repetitive nature of these genes raises the concerns over the stability of the genes and the possibility of recombination. The repeats
15 can be avoided based on suggestions offered, for example, by Arcidiacono *et al.*, Appl. Microbiol. Biotechnol. 49: 31-38, 1998; Fahnestock and Irwin (*supra*). Furthermore, a series of constructs can be generated using a similar strategy (Fahnestock and Irwin, Appl. Microbiol. Biotechnol. 47: 23-32, 1997), generating 4-20 (or more) consecutive repeats, and can be tested in cell lines prior to the generation of transgenic animals.

20 Blocks of synthetic repeats are constructed so they have different sizes and contain non-coding sequences (*e.g.*, introns from casein or immunoglobulin genes) in order to facilitate transcription of the encoded biofilament and enhance expression. The blocks can be alternating using head-to-tail construct strategy (McGrath, K. P., Ph.D. Dissertation, University of Massachusetts at Amherst, 1991; Ferrari *et al.*, U.S.P.N.

5,243,038).

Codon selection may also be designed to maximize expression, since premature termination may occur if the gene contains a greater number of codons recognized by tRNA species present in lower abundance in the cell (Rosenberg *et al.*, J. Bacteriol. 175: 716-722, 1993, Manley, J. Mol. Biol. 125:407-432, 1978). The genes to be expressed are designed and synthesized using codons favored in the tissue being expressed (*i.e.*, casein genes in the mammary gland; uroplakins in the bladder).

Given the high frequency of alanine residues in biofilament proteins, it may be desirable to supplement the cell culture media of the the cell line with additional ala and/or gly amino acids to prevent the depletion of Ala tRNA and/or Gly tRNA pools from being the rate-limiting step to generating the biofilament protein.

IV. Assembly of Expression Vectors

Eukaryotic expression vectors may be generated which drive the synthesis and secretion of proteins (*e.g.*, biofilament proteins) in the milk or urine of an animal transgenic for a nucleic acid molecule encoding such a protein. These vectors are prepared according to standard molecular biology techniques.

The synthesized nucleic acid molecule(s) may have a sequence encoding an epitope tag attached for easy identification and/or purification of the encoded polypeptide. Such purification may be accomplished, for example, by affinity chromatography for the epitope tag. A site-specific proteolytic or chemical agent recognition site may be added to the sequence to facilitate removal of the epitope tag following purification of epitope-tagged polypeptides (Saito *et al.*, J. Biochem. 101: 123-134, 1987). Preferably, the sites and site-specific proteolytic agents cleave at or near the junction of the epitope tag and the biofilament protein.

A variety of chemical cleavage agents and their recognition sites (in single letter code) are known in the art, and include the following: Hydroxylamine (N or G); formic acid (D or P), cyanogen bromide (M); or acetic acid (D or P). For example, a cyanogen bromide (CNBr) may be used to cleave a Met (M) residue introduced between the epitope tag and the biofilament protein.

Alternatively, natural or synthetic proteases may be used. Examples of these (and their recognition sites) include enterokinase (DDDK; SEQ ID NO: 5); Factor Xa (IEGR; SEQ ID NO: 6); chymotrypsin (W and Y and F); renin (YIHPFHLL; SEQ ID NO: 7); trypsin (R and K); and thrombin (RGPR; SEQ ID NO: 8). For example, the epitope tag may be attached to the biofilament via a thrombin-recognition site. Following affinity purification of epitope tag-containing proteins, since biofilaments are generally resistant to proteolysis, the epitope tag may be easily removed upon proteolytic cleavage with thrombin.

The expression cassette consists of elements necessary for proper transcription, translation, and secretion in the desired eukaryotic cell (*i.e.*, a promoter, signal sequence for secretion, intron sequences, and a polyadenylation signal). Many milk or urine specific promoters can be used with their signal sequences or with the silk and/or fibroin gene signal sequence. In the former case, the biofilament-encoding nucleic acid molecule should not contain its own translation initiation codon but, rather, should be in frame with the 3' end of the signal sequence. The 3' end of the biofilament-encoding nucleic acid molecule may contain its own polyadenylation signal, or may contain the 3' untranslated sequence normally found on the gene used for the promoter and/or signal sequence. For example, a biofilament-encoding nucleic acid molecule may be in an expression vector cassette with a promoter, signal sequence, and 3' untranslated sequence all from the same casein gene.

3527E9" 8T504050
The eukaryotic expression constructs to be used may include one or more of the following basic components.

A) Promoter of transcriptional initiation regulatory region

5 These sequences may be heterologous to the cell to be modified and may include synthetic and natural viral sequences (*e.g.*, human cytomegalovirus immediate early promoter (CMV); simian virus 40 early promoter (SV40); Rous sarcoma virus (RSV); or adenovirus major late promoter) which confers a strong level of transcription of the nucleic acid molecule to which they are operably linked. The promoter can also be modified by the deletion of nonimportant sequences and/or addition of sequences, such as
10 enhancers (*e.g.*, an enhancer element CMV, SV40, or RSV), or tandem repeats of such sequences. The addition of strong enhancer elements may increase transcription by 10-100 fold. Expression from the above-identified viral promoters is constitutive (*i.e.*, expression occurs in the absence of an apparent external stimulus).

Alternatively, for expression in the milk, for example, the promoter region may be
15 native to a ruminant mammary-specific gene. Examples include: α S1-casein (PCT Application Nos.: WO91/08216 and WO93/25567), α S2-casein, β -casein (Rosen, J.M., U.S.P.N. 5,304,489; Lee *et al.*, Nucleic Acids Res. 16: 1027-1041, 1988), κ -casein, β -lactoglobulin, and α -lactalbumin (Vilotte *et al.*, Eur. J. Biochem. 186: 43-48, 1989; PCT Application No.: WO88/01648). These promoters can drive a high level of expression of
20 a variety of proteins in a tissue and lactation specific manner.

B) Intron Inclusion

Genes containing an intron (*i.e.*, genomic clones) are expressed at higher levels than intron-less genes. Hence, inclusion of an intron placed between the transcription initiation site and the translational start codon, 3' to the translational stop codon, or inside
25 the coding region of the biofilament-encoding gene may result in a higher level of

expression.

The intron sequence includes a 5' splice site (donor site) and a 3' splice site (acceptor site). Sequences of at least 100 base pairs are found between these two sites. The origin of these intronic sequences will be derived from the promoter being used, or from the native gene (Ichimura and Mita, J. Mol. Evol. 35: 123-130, 1992) and positioned 5' to the coding sequence of the silk or fibroin gene. Since the highly repetitive nature of the construct raises concerns over the stability of the gene and the possibility of recombination due to the repetitive sequences, they can be disrupted by inserting the introns of the gene from which the promoter is used. The introns can be positioned in a manner similar to those present in the fibroin gene of *Bombyx mori* (Tsujimoto and Suzuki, Cell 18: 591-600, 1979; Tsujimoto and Suzuki, Cell 16: 425-436, 1979). This strategy will allow for increased levels of expression in addition to increased stability of the gene.

C) Signal (Leader) Sequences

Each expression vector will contain a signal sequence which directs the expressed gene product to be secreted from the mammary or uroepithelial cells. This signal sequence is present in any gene which is secreted naturally. A signal sequence from a relative fibroin gene (*e.g.*, *B. mori* heavy and light fibroin gene, P25 and ssp160), from a gene specific to the tissue of expression (*e.g.*, casein or uroplakin gene), or a general signal sequence (*e.g.*, from human alkaline phosphatase, mellitin, and CD33 signal peptides) may be used. Furthermore, the signal sequences for secretion may be interchanged between mammalian/insect genes; for example, signal sequences from mellitin, casein, or the sequences from native silk (from arachnids) or fibroin (from insects) genes may be used.

D) Termination Region

5 The transcription termination region of the nucleic acid constructs may involve the 3'-end and polyadenylation signal from which the 5'-promoter region is derived. For example, the bovine α S1 casein gene. Alternatively, the 3'-end of the nucleic acid construct will contain transcription termination and polyadenylation signals which are known to regulate post-transcriptional mRNA stability such as those derived from bovine growth hormone, β -globin genes, or the SV40 early region.

E) Other features of the expression vectors

10 The expression vectors designed for gene transfer also contain an origin or replication for propagation in *E. coli*, SV40 origin of replication, ampicillin resistance gene, neomycin resistance gene for selection in eukaryotic and/or genes (*i.e.*, dihydrofolate reductase gene) that amplify the dominant selectable marker plus the gene of interest. In addition, the expression vectors may contain appropriate flanking sequences at their 5' and 3' ends that will allow for enhanced integration rates in the transduced cells (ITR sequences; Lebkowski *et al.*, Mol. Cell. Biol. 8: 3988-3996, 1988).
15 Furthermore, prolonged expression of the silk or fibroin protein *in vitro* may be achieved by the use of sequences (*i.e.*, EBNA-1 and oriP from the Epstein-Barr virus) that allow for autonomous replication (the transduced, circular nucleic acid replicates as a plasmid in mammalian cells).

20 To clone and propagate large segments of DNA, cosmids are the vectors of choice. Although plasmid vectors can, in theory, carry large inserts, the resulting recombinants transform *Escherichia coli* very inefficiently. Cosmids have the capacity to propagate large pieces of foreign DNA (Royal *et al.*, Nature 279: 125, 1979).

25 The expression vectors used for the generation of transgenic animals may be linearized by restriction endonuclease digestion prior to transformation of a cell. In a variant of this method, only a digestion fragment that includes the coding, 5'-end

regulatory sequences (e.g., the promoter), and 3'-end regulatory sequences (e.g., the 3' untranslated region) from, for example, bovine casein or growth hormone sequences, will be used to transform cells. A cell transformed with such a fragment will not, consequently, contain any sequences that are necessary solely for plasmid propagation in bacteria (e.g., the cell will not contain the *E. coli* origin or replication or a nucleic acid molecule encoding an antibiotic-resistance protein (e.g., an ampicillin-resistance protein) that is useful for selecting prokaryotic cells).

In another variant of this method, the digestion fragment used to transform a cell will include the coding region, the 5' and 3' regulatory sequences, and a nucleic acid molecule (including a promoter and 3' untranslated region) encoding a protein capable of conferring resistance to a antibiotic useful for selecting eukaryotic cells (e.g., neomycin or puromycin).

The biofilament gene of interest may be modified in its 5' untranslated region (UTR), its 3' UTR, and/or its region coding for the N-terminus in order to preferentially improve expression. Alternatively, sequences within the coding sequence of the biofilament encoding-nucleic acid molecule may be deleted or mutated in order to increase secretion and/or avoid retention of the gene product within the cell due, for example, to the presence of endoplasmic reticulum (ER) retention signals or other sorting inhibitory signals. Furthermore, the transgenic construct may contain sequences that possess chromatin opening domain activity such that they confer reproducible activation of tissue-specific expression of a linked transgene (Ellis *et al.*, PCT Application No.: WO95/33841; Chung and Felsenfield, PCT Application No.: WO96/04390).

V. Testing and Characterization of Expression Vectors

The assembled constructs are partially characterized by sequencing the areas

where two pieces of DNA have been fused together by ligation. A partial restriction endonuclease map will provide information on the correct orientation of the ligated regulatory sequences with respect to the biofilament-encoding nucleic acid molecule.

Further characterization of the functionality of the assembled constructs include
5 their transfection into established mammary epithelial cell lines (*e.g.*, MAC-Ts) (see Turner and Huynh, U.S.P.N. 5,227,301; Huynh *et al.*, Exp. Cell. Res. 197: 191-199, 1991; Stampfer *et al.*, U.S.P.N. 4,423,145) and identification of the secreted product.

The recombinant DNA methods employed in practicing the present invention are standard procedures that are well known to those skilled in the art of molecular biology,
10 and are described in detail in, for example, Sambrook, Fritsch and Maniatis, Molecular Cloning: A Laboratory Manual (2nd ed.), Cold Spring Harbor Press, 1989; Ausubel *et al.* Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY, 1994; and Perbal, B.V., A Practical Guide to Molecular Cloning (2nd ed., John Wiley & Sons, New York, NY, 1988. For purposes of explanation only, the biofilament gene used in the
15 following examples is the 1.5 kb NcDS-1 insert described and cloned by Arcidiacono *et al.*, Appl. Microbiol. Biotechnol. 49: 31-38, 1998.

The following examples are meant to illustrate, and do not limit, the invention.

Example 1: The Casein Promoter

In the following example, the design of the construct includes the use of the goat
20 β -casein promoter (Ebert *et al.*, Bio/Technology 12: 699-701, 1993), followed by its own signal sequence for expression, followed by a 1.5 kb insert containing the silk clone (Arcidiacono *et al.*, *supra*) in frame with the 5' and 3' ends of the casein gene. A schematic diagram of this construct is shown in Fig. 1A.

09040518-034798
8547E0"BT504050

The nucleic acid molecule encoding a biofilament (*e.g.*, a silk or fibroin gene, or fragment thereof) is fused to the casein promoter and secretion of the biofilament protein is driven by signal sequences from the gene from which the promoter is derived, or from the biofilament nucleic acid molecule to be expressed. Termination sequences can be derived from the biofilament gene itself, or from the promoter gene. Furthermore, a hybrid gene can be created to increase the level of expression. For this purpose, the silk or fibroin gene (or fragment thereof) can be inserted between exon 2 (just upstream of the ATG) and exon 7 (downstream of the stop codon) of the goat β -casein gene (Ebert *et al.*, *Bio/Technology* 12: 699-701, 1993). Since the highly repetitive nature of the construct raises concerns over the stability of the gene and the possibility of recombination due to the repetitive sequences, they can be disrupted by inserting the introns from the casein gene (introns 3 to 7). Construction of the vector can be performed in a cosmid vector (supercos), due to the large size of the final construct or the backbone of the plasmid could consist of any known bacterial vector (preferably ones that accept large DNA sizes) which contains sequences necessary for its amplification in an *E. coli* host (Sambrook *et al.*, *supra*).

Example 2: The Whey Acidic Protein (WAP) Construct

The present example demonstrates the generation of a hybrid gene composed of the WAP gene promoter, its signal sequence, a 1.5 kb cDNA encoding dragline silk (Arcidiacono *et al.*, *supra*), followed by the 3' end of the WAP gene (Velandar *et al.*, *Proc. Natl. Acad. Sci U.S.A.* 89: 12003-12007, 1992). The details of its construction are described below and diagrammed in Fig. 1B.

Whey acidic protein (WAP), the major whey protein in rodents, is expressed at high levels exclusively in the mammary gland during late pregnancy and lactation (Hobbs

et al., J. Biol. Chem. 257: 3598-3605, 1982). The genomic murine WAP gene consists of 2.6 kbp (kilo base pairs) of 5' flanking promoter sequence, 3.0 kbp of coding sequence (exons and introns), and 16 kbp of 3' flanking DNA (see Fig. 1B) (Velandar *et al.*, Proc. Natl. Acad. Sci U.S.A. 89: 12003-12007, 1992; Velandar *et al.*, Ann. N. Y. Acad Sci. 665: 391-403, 1992).

In one example, a hybrid gene composed of the WAP gene promoter and a cDNA encoding dragline silk may be constructed. The hybrid dragline-silk encoding gene is created by inserting the gene(s) or nucleic acid molecule(s) of interest (in this case, a cDNA encoding dragline silk) between the murine WAP promoter and 5' sequence (nucleotide position -949 to +33) at the 5' end and the WAP 3' sequence at the 3' end (843 bp; portion of exon 3, last 30 bases and all of intron C, exon 4, and 70 bp of 3' UTR) (Campbell *et al.*, Nucleic Acids Res. 12: 8685-8697, 1984). In this example, the signal sequence comes from the native silk gene. One can also use the WAP gene signal sequence by including an additional 56 bp at the 5' end (position -949 to +89).

In another example, the hybrid gene is created by inserting nucleotide sequence encoding part of the 5' untranslated region and a 19 amino acid signal sequence from the murine WAP gene (nucleotides +1 to +90) (Hennighausen *et al.*, Nucl. Acids Res. 10: 3733-3744, 1982), and by amplifying the 1.5 kb (kilo base) silk gene (NsDS-1; Arcidiacono *et al.*, *supra*) using 5' primers containing the 90 bp (base pair) sequence encoding the signal sequence flanked by a KpnI restriction endonuclease recognition site. The amplification is performed to maintain the correct reading frame, and 3' primers creating a KpnI restriction endonuclease recognition site at the 3' end of the gene. This PCR product is then insert at the KpnI site at the first exon of WAP. The hybrid gene can be cut out of the vector by digestion with the EcoRI restriction endonuclease (see Fig. 1B), and purified for microinjection.

Example 3: The Uroplakin Promoter

In these experiments, the uroplakin II promoter (Lin *et al.*, Proc. Natl. Acad. Sci. U.S.A. 92:679-683, 1995; Sun, T., PCT Application No.: WO96/39494) is used to drive the expression of the fibroin or silk gene(s) in the urothelium of transgenic animals. The fibroin or silk gene(s) is inserted downstream of a 3.6 kb 5' flanking sequence of the mouse uroplakin II (UPII) gene (Lin *et al.*, Proc. Natl. Acad. Sci. U.S.A. 92:679-683, 1995). A sequence containing part of exon 1 and all of intron 1 and exon 2 of the mouse protamine-1 (Mp-1) gene (Peschon *et al.*, Proc. Natl. Acad. Sci. U.S.A. 84: 5416, 1987) is placed at the 3' end of the gene to provide an exon/intron splicing site and a polyadenylation signal. One can also use the signal sequence of the uroplakin II gene by inserting the fibroin or silk-encoding gene, or fragment thereof (mature protein only), in frame to amino acid 59 of exon 3. A diagram of this construct is shown on Fig. 1C.

Example 4: DNA Shuffling

Another method for producing a biofilament-encoding gene cassette is by DNA shuffling. DNA shuffling is a process for recombination and mutation, performed by random fragmentation of a pool of related genes, followed by reassembly of the fragments by primerless PCR (Stemmer, W. P., Nature 370: 389-391, 1994; Stemmer, W. P., Proc. Natl. Acad. Sci. U.S.A. 91: 10747-10751, 1994). The goal of DNA shuffling is to optimize the function of genes without first determining which gene product is rate limiting. Genes themselves can be "shuffled," or can be from different species (*i.e.*, spidroin 1 and 2 and ADF 1-4). Furthermore, different repeats (*e.g.*, GGAGQGGY (SEQ ID NO: 4) from ADF 3) within one species can be "shuffled" (with, for example, repeats from ADF 1, 2, and 4) and expressed to determine the combination which yields favorable characteristics. In addition to point mutation, diversity is generated using a

wide variety of mutational mechanisms, such as polynucleotide deletion, insertion, and inversion, as well as integration and excision. Once thus generated, the biofilament-encoding nucleic acid molecule may be inserted into an expression cassette for secretion in milk or urine, and used to transform mammalian cells.

5 Example 5: Constructs Expressing Two Genes

For the expression of two genes (*e.g.*, dragline silk consists of a ratio of ADF3 and 4), either two separate constructs can be generated, or both genes can be cloned into the same expression cassette with the insertion of an intervening ribosomal entry site (IRES) (Jang *et al.*, J. Virol. 62: 2636-2643, 1988). The advantage to cloning both genes into the
10 same expression cassette is that only one single construct is needed to generate the transgenic animal.

Example 6: Synthesis of Chimeric or Hybrid Biofilaments

Chimeric molecules are synthesized that include a fusion of the silk (containing either crystal or amorphous domains) in frame with one or more domains of collagen or
15 fibrillin, that may allow for increased crosslinking, stability, or elasticity. Such a chimera is especially useful as a surgical biomaterial.

Example 7: Production of Biofilaments in Mammary Epithelial or Uroepithelial Cell Lines

The synthesized biofilament-encoding nucleic acid molecules of the invention are
20 produced in homologous biologically relevant cell culture systems. Genetic stability of the synthetic genes, secretion ability, and attributes of the produced biofilament(s) can, thus, be evaluated very efficiently before transgenic animal studies are initiated.

3527E0" 034798
Mammary epithelial and urine-producing cell lines are transfected according to standard techniques (see, *e.g.*, Ausubel *et al.*, *supra*) with their respective plasmids (*e.g.*, a milk-specific promoter containing expression construct is transfected into mammary epithelial cells). In one example, to demonstrate the secretion of the produced spider silk(s), culture media is harvested from the stable cell lines (24-96 hours post-differentiation for mammary epithelial cells) and resolved by SDS-PAGE for Western blotting analysis using anti-spider silk antibodies (commercially available from Monsanto, St. Louis, MO), or antibodies raised against peptides having sequences homologous to SEQ ID Nos: 1-4.

10 Example 8: Generation of Transgenic Animals Expressing Biofilament(s) in Milk or Urine

15 In some methods of transgenesis, transgenes are introduced into the pronuclei of fertilized oocytes. For some animals, such as mice, fertilization is performed *in vivo* and fertilized ova are surgically removed. In other animals, the ova can be removed from live, or from newly-dead (*e.g.*, slaughterhouse) animals and fertilized *in vitro*. Transgenes are usually introduced by microinjection (Ogata *et al.*, U.S.P.N. 4,873,292). The microinjected zygotes are transferred to an appropriate female resulting in the birth of a transgenic or chimeric animal, depending upon the stage of development when the transgene is integrated. Chimeric animals can be bred to form true germline transgenic animals.

20 Alternatively, transgenes can be introduced into embryonic stem cells (ES cells). Transgenes can be introduced into such cells by electroporations, microinjection, or any other techniques used for the transfection of cells which are known to the skilled artisan. Transformed cells are combined with blastocysts from the animal from which they

originate. The cells colonize the embryo, and in some embryos these cells form the germline of the resulting chimeric animal (Jaenisch, R., Science 240: 1468-1474, 1988). Alternatively, ES cells can be used as a source of nucleic for transplantation into an enucleated fertilized oocytes, thus giving rise to a transgenic animal.

5

Production of a Biofilament in Milk

In one example, the spider silk gene is subcloned into an expression vector that contains a casein gene promoter, such that the expression of the spider silk gene is controlled by the casein gene promoter. One such expression vector is a casein
10 expression vector based on the vectors described by Rosen, J. M. (U.S.P.N. 5,304,489) and Meade and Lonberg (U.S.P.N. 4,873,316).

In another example, the WAP/silk gene hybrid fragment (the EcoRI fragment described above in Example 2) is purified and microinjected into fertilized mouse eggs, which are then implanted into foster mothers. The presence of the WAP/silk gene is
15 identified by Southern blot analysis of tail DNA (DNA isolated from tail tissue) in accordance with methods well known in the art. Positive founder animals are then back-crossed to generate hemizygous animals that are used for studying transgene expression.

Production of a Biofilament in Urine

The spider silk gene, for example, may be subcloned into an expression vector
20 such that the spider silk gene is under the transcriptional control of the uroplakin promoter (described by Lin *et al.*, Proc. Natl. Acad. Sci. U.S.A. 92:679-683, 1995).

Urine has the added advantage that its pH and salt composition can be modulated to allow for the incorporation of certain components that may influence the formation of the silk in a most native structure.

Example 9: Generation of “Double Transgenic” Animals that Produce Biofilaments in Both Milk and Urine

A transgenic animal may be generated that produces a biofilament protein (*e.g.*, spider silk) in both its urine and its milk. One method for constructing such an animal is to transform an embryonal cell of the animal with two constructs, one construct in which the expression of the biofilament-encoding nucleic acid molecule is directed by a promoter capable of expressing and secreting the biofilament from a milk-producing cell; and a second construct in which the expression of the biofilament-encoding nucleic acid molecule is directed by a promoter capable of expressing and secreting the biofilament from a urine-producing cell. In this method, the doubly-transformed cell is used to generate a transgenic animal.

Hence, mammalian (*e.g.*, ruminant) zygotes are microinjected (or co-microinjected) with two nucleic acid fragments: one that expresses the biofilament protein under the control of a milk promoter, and one that expresses the biofilament protein under the influence of a urine specific promoter. The generated transgenic animal will be secreting/producing the biofilament in both its milk and in its urine. This will increase the total output of biofilaments produced per transgenic animal unit.

A second method for producing such an animal capable of producing a biofilament in both its milk and its urine is to separately generate an embryonic stem cell carrying a construct capable of expressing and secreting the biofilament in a milk-producing cell and an embryonic stem cell carrying a construct capable of expressing and secreting the biofilament in a urine-producing cell. Both transformed ES cell types are then combined with blastocysts from the animal from which they originate to produce chimeric animals, which may then be bred to homozygosity.

This type of double-expressing animal has a number of advantages. First, animals

of both genders will produce biofilaments in the urine on a continual basis from birth, and female animals will then be able to produce additional biofilament protein in their milk as a lactating adult. And second, the amount of biofilament produced by any individual female animal may be increased (by inducing lactation) or reduced (by not inducing
5 lactation) as the need for biofilament changes.

Example 10: Generation of transgenic animals that coexpress and assemble a Biofilament protein from two monomers

A transgenic animal may be generated that produces two proteins which are both required for the correct assembly of a biofilament protein in its milk, urine, or both. For
10 example, *Araneus diadematus* dragline silk consists of a ratio of ADF3 and 4). One method for constructing such an animal is to transform an embryonal cell of the animal with two constructs, each expressing one the two proteins. These proteins may be expressed in the urine or milk, or both.

In a second method, the construct described in Example 5 which encodes a
15 polycistronic message may be employed. This construct may be able to secrete its products in the milk, urine, or both. Once the two proteins are present in the same fluid (*i.e.*, both in the milk or both in the urine), they can assemble correctly and be purified.

What is claimed is:

Claims

1. A nucleic acid molecule comprising (i) a nucleic acid sequence encoding a biofilament, (ii) a promoter that directs expression of a polypeptide in milk-producing cells or urine-producing cells, said promoter operably linked to said sequence, and (iii) a
5 leader sequence that enables secretion of said biofilament by said milk-producing cells or said urine-producing cells, into, milk or urine, respectively, of a mammal.

2. A mammalian embryo whose nucleus comprises the nucleic acid molecule of claim 1.

3. A female mammal in which the genome of the mammary tissue of said female
10 mammal comprises the nucleic acid molecule of claim 1, wherein said promoter is milk-producing cell-specific.

4. The mammal of claim 3, wherein said mammal is selected from the group consisting of a rodent, a ruminant, and a goat.

5. An animal in which the genome of cells that contribute to urine production in
15 said animal comprises the nucleic acid molecule of claim 1, wherein said promoter is urine-producing cell-specific.

6. The animal of claim 5, wherein said animal is a mammal.

7. The nucleic acid molecule of claim 1, wherein said biofilament is spider silk.

8. The nucleic acid molecule of claim 7, wherein said spider silk is dragline silk.

9. The nucleic acid molecule of claim 1, wherein said biofilament, when secreted such that the secretion is subjected to shear forces and mechanical extension, has a poly-alanine segment that undergoes a helix to a β -sheet transition, said transition forming a β -crystal that stabilizes the structure of said biofilament.

10. The nucleic acid molecule of claim 1, wherein said biofilament has an amorphous domain that forms a β -pleated sheet such that inter- β sheet spacings are between 3 angstroms and 8 angstroms in size.

11. The nucleic acid molecule of claim 1, wherein said biofilament has a C-terminal amino acid motif comprising an amorphous domain and a crystal forming domain, said motif having a sequence that is at least 50% identical to SEQ ID NO: 2.

12. The nucleic acid molecule of claim 1, wherein said biofilament has a consensus sequence that is at least 50% identical to SEQ ID NO: 3.

13. A method for producing a biofilament, said method comprising the steps of:

(a) providing an embryonal cell transfected with a biofilament encoding nucleic acid molecule that expresses and causes secretion of said biofilament from a cell derived from said transfected embryonal cell;

(b) growing said embryonal cell to produce an animal comprising biofilament expressing and secreting cells; and

(c) isolating said biofilament from said biofilament expressing and secreting cells

from said animal.

14. A method for producing a biofilament, said method comprising the steps of:

(a) providing an animal cell transfected with a nucleic acid molecule that contains

(i) a nucleic acid sequence encoding a biofilament, (ii) a promoter that directs expression
5 of a polypeptide in an animal cell, and (iii) a leader sequence that causes secretion of said
biofilament by said cell;

(b) culturing said transfected cell; and

(c) isolating said biofilament from the culture medium of said cultured transfected
cell.

10 15. The method of claim 13 or 14, wherein said biofilament is spider silk.

16. The method of claim 15, wherein said spider silk is dragline silk.

17. The method of claim 13 or 14, wherein said biofilament, when secreted such
that the secretion is subjected to shear forces and mechanical extension, has a poly-
alanine segment that undergoes a helix to a β -sheet transition, said transition forming a β -
15 crystal that stabilizes the structure of said biofilament.

18. The method of claim 13 or 14, wherein said biofilament has an amorphous
domain that forms a β -pleated sheet such that inter- β sheet spacings are between 3
angstroms and 8 angstroms in size.

19. The method of claim 13 or 14, wherein said biofilament has a C-terminal

amino acid motif comprising an amorphous domain and a crystal forming domain, said motif having a sequence that is at least 50% identical to SEQ ID NO: 2.

20. The method of claim 13 or 14, wherein said biofilament has a consensus sequence that is at least 50% identical to SEQ ID NO: 3.

5 21. The method of claim 13 or 14, wherein said animal is a mammal.

PRODUCTION OF BIOFILAMENTS IN TRANSGENIC ANIMALS


Abstract of the Disclosure

Disclosed is a method for the recombinant production of biofilaments, such as spider silk or insect fibroins, using transgenic animals which secrete the biofilaments in their milk and/or urine, and transgenic cells which secrete the biofilaments into culture media. Such a method is useful for producing large quantities of biofilament material. Also disclosed is a nucleic acid molecule for generating such transgenic animals.

\\Ceserver\documents\06632\06632.011001 appln.wpd

03040513.03493
SECRET

Figure 1A beta casein/ NcDS-1



20040313 09:49:26

Figure 1B WAP/NcDS-1 construct





Figure 1C Uroplakin II/ NcDS-1 construct



9527ED" BT50-060

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled PRODUCTION OF BIOFILAMENTS IN TRANSGENIC ANIMALS, the specification of which

☒ is attached hereto.

☐ was filed on _____ as Application Serial No. _____
and was amended on _____.

☐ was described and claimed in PCT International Application No. _____
filed on _____ and as amended under PCT Article 19 on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Serial Number	Filing Date	Priority Claimed?
			Yes/No
			Yes/No
			Yes/No

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information I know to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

COMBINED DECLARATION AND POWER OF ATTORNEY

Serial Number	Filing Date	Status

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Paul T. Clark, Reg. No. 30,162, Karen L. Elbing, Reg. No. 35,238, Kristina Bieker-Brady, Reg. No. 39,109, and Evelyn D. Shen, Reg. No. 39,834.

Address all telephone calls to: Paul T. Clark at 617/428-0200.

Address all correspondence to: Paul T. Clark, Esq. at Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
Costas N. Karatzas	Quebec, Canada	251 Sherwood, Beaconsfield, Quebec, Canada H9W 2H4	Greek
Signature:			Date:

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
Jeffrey D. Turner	Quebec, Canada	1 Riley Road, Hudson, Quebec, Canada J0P 1H0	Canadian
Signature:			Date:

B647E0" BT504060

COMBINED DECLARATION AND POWER OF ATTORNEY

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
Anthoula Lazaris-Karatzas	Quebec, Canada	251 Sherwood, Beaconsfield, Quebec, Canada H9W 2H4	Canadian
Signature:			Date:

Applicant or Patentee : Costas N. Karatas et al.
 Serial or Patent No. :
 Filed or Issued : March 17, 1998
 Title : PRODUCTION OF BIOFILAMENTS IN TRANSGENIC ANIMALS

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
 (37 CFR 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN**

I hereby declare that I am

- ☐ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

Name of Small Business Concern: NEXIA BIOTECHNOLOGIES, INC.

Address of Small Business Concern: 21,111 LAKESHORE ROAD, STE. ANNE DE BELLEVUE, QUEBEC, CANADA

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled PRODUCTION OF BIOFILAMENTS IN TRANSGENIC ANIMALS by inventors Costas N. Karatzas, Jeffrey D. Turner, Anthoula Lazaris-Karatzas described in

- ☒ the specification filed herewith.
☐ application serial no. _____, filed _____.
☐ patent no. [**PATENT NUMBER**], issued [**ISSUE DATE**].

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e). NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

Assignee Name:

Assignee Address:

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent on which this verified statement is directed.

Name: Jeffrey D. Turner, Ph.D.

Title: President and Chief Executive Officer

Address: Nexia Biotechnologies, Inc., 21,111 Lakeshore Road, Ste. Anne De Bellevue, Quebec, Canada

Signature: _____ **Date:** _____

09040318 031798